<DOC>
	<DOCNO>NCT02337764</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety TVP-1012 ( 1 mg/day ) levodopa Japanese participant Parkinson 's disease .</brief_summary>
	<brief_title>A Long-term , Phase 3 Study TVP-1012 ( 1 mg ) Levodopa Treated Parkinson 's Disease Participants</brief_title>
	<detailed_description>This multicenter , open-label , long-term , phase 3 study evaluate safety efficacy long-term administration TVP-1012 1 mg levodopa Japanese participant Parkinson 's disease . The study period consist 2-week screening period subsequent 52-week treatment period . Participants fulfil inclusion criterion meet exclusion criterion start screen period ( Week -2 ; Visit1 ) also end screen period ( Week 0 ; Visit 2 ) enrol study , receive 1 mg TVP-1012 daily 52 week , unblinded manner , day Visit 2 .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>The participant diagnosis Parkinson 's disease accord diagnostic criterion UK Parkinson 's Disease Society Brain Bank . The participant receive levodopa combination drug &gt; = 1 month either follow . Wearing phenomenon Decreased response levodopa combination drug The participant receive levodopa combination drug without change dose regimen . The participant outpatient either sex age &gt; = 30 &lt; 80 year . The participant Modified Hoehn &amp; Yahr stage 5 ( stage 5 eather ontime offtime participant wear phenomenon ) . The participant severe dyskinesia . The participant unstable systemic disease . The participant MiniMental State Examinations ( MMSE ) score &lt; = 24. psychiatric disease . The participant history clinically significant hypertension reaction associate ingestion tyraminerich food . The participant receive neurosurgical intervention Parkinson 's disease ( e.g. , pallidotomy , thalamotomy , deep brain stimulation ) . The participant receive transcranial magnetic stimulation within 6 months.The participant receive selegiline , pethidine , tramadol , reserpine methyldopa within 90 day . The participant receive levodopa monotherapy , psychoneurotic agent antiemetic medication dopamine agonist within 14 day . However , participant receive quetiapine domperidone stable dose regimen &gt; = 14 day may include study . The participant require take excluded medication treatment . The participant laboratory data meeting following : Creatinine &gt; = 2 x upper limit normal ( ULN ) Total bilirubin &gt; = 2 x ULN ALT AST &gt; = 1.5 x ULN ALP &gt; = 3 x ULN The participant receive excluded medication treatment .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>